Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Genomic dark matter that matters
- Starting with the “not-so-old” dogma
- Cancer: a complex genetic disease
- microRNAs discovery
- What are microRNAs?
- miRNAs make big splash
- 2014 miRNA heresies
- miRNAs are non-coding RNAs in high eukaryotes
- When was the first microRNA discovered?
- miRNAs in physiological processes
- Alterations of non-coding RNAs in human disease
- miRNAs and human diseases
- ncRNA expression profiles in cancer
- Abnormal miRNA expression - “in cascade” model
- A non-coding RNA revolution in the cancer society
- miR15a/miR16-1 deletion/down-regulation in B-CLL
- miR/Tp53 pathogenic & prognostic CLL model
- CAGRs and microRNAs
- microRNAs as oncogenes and tumor suppressors
- microRNAs - mechanisms of action (1)
- microRNAs - mechanisms of action (2)
- microRNAs - mechanisms of action (3)
- microRNAs - steering wheel of tumor metastases
- The same miRNA - angel and devil?
- microRNA: an oncogene and tumor suppressor
- miR alterations and cancer predisposition
- Cancer predisposition: epidemiology to genetics
- miR15a/miR16-1 transcript germline abnormalities
- Humans and mice: same mutation, same disease
- SNPs in miRs could predispose to familial cancer
- Genomic variations in miRNA target cancer genes
- miRNAs - the missing link in cancer predisposition
- miRNA profiling: diagnostic & prognostic tool
- Unique miRNA signature and CLL progression
- Unique miRNA signature and CLL prognosis
- Unique miRNA signature & lung cancer prognosis
- miR gene expression deregulation in breast cancer
- miR-21 in tumors & receipt of chemotherapy
- microRNAs in plasma - the oldest hormones
- Plasma miR for treatment and outcome prediction
- Xeno-miRs: viral miRs plasma levels in sepsis
- miRNAs as new therapeutic targets & drugs (1)
- miRNAs as new therapeutic targets & drugs (2)
- The basic principles of miRNA-based therapy
- RNA inhibition agents targeting malignant cells (1)
- RNA inhibition agents targeting malignant cells (2)
- Silencing miRNAs with antagomirs
- microRNA sponges
- miRNAs efficiency in specific killing of cancer cells
- miR-15/miR-16: apoptosis & cancer-related genes
- Two strategies: RNA inhibition in human cancers
- Discovering small ncRNAs - a never ending job!
- ncRNA dictionary of the human genome
- lncRNAs – mechanisms of action
- lncRNAs are involved in various cellular contexts
- Dodecalogus for ncRNA believers (1)
- Dodecalogus for ncRNA believers (2)
- Dodecalogus for ncRNA believers (3)
- Dodecalogus for ncRNA believers (4)
- Dodecalogus for ncRNA believers (5)
- Dodecalogus for ncRNA believers (6)
- Dodecalogus for ncRNA believers (7)
- Dodecalogus for ncRNA believers (8)
- Dodecalogus for ncRNA believers (9)
- Dodecalogus for ncRNA believers (10)
- Revisiting the molecular oncology dogma
Topics Covered
- Cancer: a complex genetic disease
- microRNAs discovery
- miRNAs in physiological processes
- Alterations of non-coding RNAs in human disease
- ncRNA expression profiles in cancer
- Abnormal miRNA expression – “in cascade” model
- A non-coding RNA revolution in the cancer society
- microRNAs as oncogenes and tumor suppressors
- miR alterations and cancer predisposition
- SNPs in miRs could predispose to familial cancer
- microRNAs in plasma
- miRNAs as new therapeutic targets & drugs
- lncRNAs – mechanisms of action
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Calin, G. (2015, November 30). The non-coding RNA revolution in the cancer society [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/MQCQ9714.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. George Calin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Cancer Genetics
Transcript
Please wait while the transcript is being prepared...
0:00
Hello to everybody.
As usual, it's my pleasure
to present to you
what I like to do more after
playing with my kids,
playing with microRNAs
and non-coding RNAs.
My name is George Calin,
I'm a professor
in MD Anderson Cancer Center
and I will tell you today about
the non-coding RNA revolution
in the cancer society.
0:23
Basically what is new
and what is wonderful in science
is the fact that you never know
what the next day
is bringing you.
Genomics was bringing
to the scientists
working in this field basically
the so-called Dark Matter.
It's a part of the genome
that is not transcribed
in protein coding genes.
So therefore was supposed to be
the trash can of the genome.
By analyzing data
and by analyzing transcripts,
in this place where nobody
was looking for,
starting about
two decades again,
genetics turned around
and basically now
it's full of over 1 million
so-called non-coding RNAs.
These RNAs
who did not codify or proteins
but regulates this expression
of protein coding genes,
and this is the main topic
of my presentation today.
1:16
Basically, the dogma
of molecular biology
was very simple,
and everybody was believing
this is final truth of genomics.
DNA is the most important,
is transcribed in RNAs
who are translated to proteins.
RNAs were considered
intermediary of genetic flow,
so very few people
were interested in
understanding
how really RNA was working.
There were some flagging
discovery showing
that RNAs are not bystanders
in the dogma like
the identification of ribozymes
or the identification of editing,
but still RNAs were considered
secondary player in the game.